Evidence that maturation of the N-linked glycans of the respiratory syncytial virus (RSV) glycoproteins is required for virus-mediated cell fusion: The effect of α-mannosidase inhibitors on RSV infectivity  by McDonald, Terence P. et al.
6) 289–301
www.elsevier.com/locate/yviroVirology 350 (200Evidence that maturation of the N-linked glycans of the respiratory syncytial
virus (RSV) glycoproteins is required for virus-mediated cell fusion:
The effect of α-mannosidase inhibitors on RSV infectivity
Terence P. McDonald a, Chris E. Jeffree b, Ping Li a, Helen W. McL. Rixon a, Gaie Brown a,
James D. Aitken c, Kirsty MacLellan a, Richard J. Sugrue a,⁎,1
a MRC Virology Unit, Institute of Virology, Church Street, Glasgow G11 5JR, UK
b Institute of Cell and Molecular Biology, Biological Sciences EM Facility, Waddington Building, King's Buildings, Mayfield Road, University of Edinburgh,
Edinburgh EH9 3JN, UK
c Division of Virology, Institute of Virology, Church Street, University of Glasgow, Glasgow G11 5JR, UK
Received 9 December 2005; returned to author for revision 6 January 2006; accepted 19 January 2006
Available online 2 March 2006Abstract
Glycan heterogeneity of the respiratory syncytial virus (RSV) fusion (F) protein was demonstrated by proteomics. The effect of maturation of
the virus glycoproteins-associated glycans on virus infectivity was therefore examined using the α-mannosidase inhibitors deoxymannojirimycin
(DMJ) and swainsonine (SW). In the presence of SW the N-linked glycans on the F protein appeared in a partially mature form, whereas in the
presence of DMJ no maturation of the glycans was observed. Neither inhibitor had a significant effect on G protein processing or on the formation
of progeny virus. Although the level of infectious virus and syncytia formation was not significantly affected by SW-treatment, DMJ-treatment
correlated with a one hundred-fold reduction in virus infectivity. Our data suggest that glycan maturation of the RSV glycoproteins, in particular
those on the F protein, is an important step in virus maturation and is required for virus infectivity.
© 2006 Elsevier Inc. All rights reserved.Keywords: Respiratory syncytial virus; Virus assembly; Fusion protein; Glycosylation; Swainsonine; Deoxymannojirimycin; ProteomicsIntroduction
Human respiratory syncytial virus (hRSV) encodes three
integral membrane proteins, namely the fusion (F), attachment
(G) and small hydrophobic (SH) proteins. The G protein
mediates attachment of the virus to the cell during virus entry,
while the role played by the SH protein during virus replication
remains to be established. During virus entry, the F protein plays
a pivotal role by mediating fusion of the virus and host-cell
membranes. Studies employing reverse genetics have shown
that whereas the F protein is essential for replication in tissue
culture, the G and SH proteins are dispensable (Bukreyev et al.,⁎ Corresponding author. Fax: +65 6791 3856.
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doi:10.1016/j.virol.2006.01.0231997; Karron et al., 1997; Whitehead et al., 1999; Techaar-
pornkul et al., 2001). The G protein is extensively modified by
O-linked glycosylation, but it is not clear to what extent it is
modified by N-linked glycosylation. In addition, only minor
amounts of the SH protein are N-linked glycosylated. In
contrast, of the three virus glycoproteins, the F protein has
relatively high levels of N-linked glycans, and evidence
suggests a role for N-linked glycosylation of the F protein in
mediating virus-mediated cell fusion (Zimmer et al., 2001b).
The F protein is synthesised initially as an inactive precursor
(F0), which undergoes proteolytic cleavage by cellular factors
in the trans-Golgi compartment, (Bolt et al., 2001; Gonzalez-
Reyes et al., 2001; Sugrue et al., 2001; Zimmer et al., 2001a).
This generates the mature and active form of the protein which
consists of the disulphide-linked subunits, F1 and F2 (Scheid
and Choppin, 1977; Gruber and Levine, 1985; Collins and
Mottet, 1991; Anderson et al., 1992a, 1992b). During its
290 T.P. McDonald et al. / Virology 350 (2006) 289–301transport through the secretory pathway, the F protein is
glycosylated by several enzyme activities in the endoplasmic
reticulum (ER) and Golgi complex (Lambert, 1988). Depending
on the RSV isolate, the F protein amino acid sequence can
contain up to 5 potential N-linked glycosylation sites. However,
experimental evidence suggests that in the mature F protein, the
F1 subunit is glycosylated at a single site, N500, while the F2
subunit is glycosylated at two different sites, namely N27 and
N70 (Collins et al., 1984; Baybutt and Pringle, 1987; Lopez et
al., 1988; Lerch et al., 1991; Zimmer et al., 2001b). Recent
reports suggest that N500 plays a role in F protein-mediated
fusion (Zimmer et al., 2001b) possibly by interacting with the
heptad repeat regions. In contrast, the role played by N27 and
N70 in the functionality of the F protein remains to be
established.
Following the exit of the F protein from the ER, each
attached glycan chain exists in a form that is characterised by a
mannose core to which chains of mannose residues are attached.
These mannose chains are removed subsequently in the Golgi
complex by Golgi-resident α-mannosidases 1 and 2 and
replaced with other terminal glycans, such as N-acetyl-
glucosamine and fucose. This process changes the structure of
the attached glycans from relatively simple structures to glycan
chains that exhibit a high degree of complexity (Anderson et al.,
1992a, 1992b; Collins and Mottet, 1991). N-linked glycosyl-
ation of the hRSV F protein does not appear to be required
either for its proteolytic cleavage or its surface expression
(Collins and Mottet, 1991). However, although there is no
apparent requirement for glycosylation in F protein transport,
evidence suggests that it may be required for post-assembly
processes that involve the virus glycoproteins (e.g., membrane
fusion, Zimmer et al., 2001b). The work described in this
manuscript examines the effect of glycan maturation on virusFig. 1. Western blot analysis of RSV-infected Hep2 cells at 24 h PI. RSV-infected (I) c
blotting using (A) MAb169 or (B) PAb922. A comparison of mock- (M) and virus-in
forms of the F protein subunits are highlighted (*), as are the positions of the molecinfectivity. Our results suggest that maturation of the glycans on
the virus glycoproteins is not required either for virus assembly
or for the incorporation of these proteins into virus particles.
However, glycan maturation is required for infectivity of
progeny virus. The correlation between glycan maturation and
at least one indicator of F protein functionality in tissue culture
(i.e., virus infectivity) points to the F protein as the major site of
action of DMJ. This suggests that the structure of the glycans
that are attached to the F protein may be essential for
determining the biological activity of this protein.
Results and discussion
The F protein exhibits heterogeneity in glycan maturation
The effect of glycosylation on F protein heterogeneity was
examined by comparing the migration of the glycosylated and
de-glycosylated forms of the F protein subunits by 2D SDS
PAGE and Western blotting analysis. The F1 and F2 subunits
were detected with MAb169 (Rixon et al., 2004) and PAb922,
respectively.
RSV-infected cells were solubilised with denaturation buffer
and incubated in the presence or absence of PNGase F as
described in Materials and methods. This enzyme is able to
remove N-linked glycans from proteins. The proteins in these
lysates were separated by SDS PAGE, transferred by Western
blotting on to PVDF membranes, and the membranes probed
either with MAb169 or PAb922 (Fig. 1). Following treatment
with PNGase F, the F1 subunit changed from a single protein
species with a mass of 55 kDa to one of 50 kDa (Fig. 1A) while
the F2 subunit changed from a single protein species with a
mass of 20 kDa to one of 10 kDa (Fig. 1B). This showed that
both subunits of the F protein were de-glycosylated efficientlyells were either untreated (−) or PNGase F-treated (+) and examined by Western
fected cells shows the specificity of PAb922. The positions of the deglycosylated
ular weight markers.
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glycosylated forms of the protein could be detected with these
antibodies.
Glycosylation of the F protein subunits from infected cells
was examined by 2D SDS PAGE using the above antibodies.
Total membranes were recovered from mock- and RSV-infected
Hep2 cells at 20 h post-infection (PI) and incubated in the
presence or absence of PNGase F, prior to preparation for 2D
SDS PAGE as described in Materials and methods. The proteins
were separated in the first dimension by isoelectric focusing
using a pH range of 3–10 and then separated in the second
dimension by SDS PAGE. A major obstacle to the analysis of
membrane proteins by 2D SDS PAGE is their hydrophobic
nature, which often results in poor resolution. However, the
sample preparation procedures described in Materials and
methods resulted in good separation and resolution of the
membrane-associated proteins by 2D SDS PAGE. This can be
seen in silver-stained polyacrylamide gels of membrane
proteins from virus-infected cells (Fig. 2A).
Following separation in the second dimension by SDS
PAGE, the proteins were transferred by Western blotting on to
PVDF membranes which were then probed either with MAb169
(Fig. 2B) or PAb922 (Fig. 2C) and the positions of the relevant
F protein spots were visualised. In the absence of PNGase F
treatment, three protein spots were observed when probed with
MAb169 (Fig. 2B (b)). Two of these were in high abundance
while a third protein spot appeared in much lesser abundance
(Fig. 2B (b), highlighted by *). Each of these proteins migrated
with a molecular mass of 55 kDa, the expected size for the F1
protein subunit. Following PNGase F-treatment, one major
protein spot with a mass of approximately 50 kDa was
observed, which is the expected size for the de-glycosylated
F1 subunit, and which accounted for 95% of the total protein
detected (Fig. 2B (c)). A minor protein of similar size was also
detected (Fig. 2B (c), highlighted by *), the significance of
which is currently unclear. In a similar analysis, in the absence
of PNGase F-treatment, probing the membrane with PAb922
showed three major protein species of 20 kDa (Fig. 2C (b)).
Treatment with PNGase F gave rise to a single major protein
species with a mass of 10 kDa (Fig. 2C (c)), the expected size
for the deglycosylated F2 subunit. A minor protein was also
observed (Fig. 2C (c), highlighted by *), the significance of
which is unclear. In addition, deglycosylation of the F1 and F2
subunits resulted in a shift to a more basic isoelectric point (PI).
The different forms of the F protein subunits, detected by 2D
SDS PAGE (Fig. 2B (b); Fig. 2C (b)), migrated with the same
molecular mass, suggesting that the same number of glycosyl-
ation sites are used by these different F protein species. Previous
studies on recombinant F protein expression have shown that
the selective removal of individual glycosylation sites results in
significant differences in molecular mass of the subunits
(Zimmer et al., 2001b). When examined by SDS PAGE, the
F2 subunit glycosylated at a single site migrates with an
apparent size of 3–4 kDa less than the subunit modified at two
sites. A similar size difference would be expected in the second
dimension if these F2 species differed in the number of attached
glycans. The change in isoelectric point presumably is aconsequence of the variation in the type of terminal carbohy-
drates that are attached to the glycans. Although this difference
would change marginally the apparent size of the glycoprotein
subunit, such subtle alterations would not be expected to give
rise to a detectable difference in molecular mass in the second
dimension under our electrophoretic conditions.
No protein products smaller than those expected were
detected by 2D SDS PAGE, suggesting that there was no
proteolytic degradation of the F protein subunits during sample
preparation. Similarly, no protein spots were observed in
material processed from mock-infected cells (Fig. 2B (a); Fig.
2C (a)), thus demonstrating the specificity of the antibodies.
Several reports have shown that during RSV infection the
G and SH proteins are expressed as glycosylated variants.
The RSV G protein is extensively modified by O-linked
glycosylation which gives rise to G protein species ranging in
size from 45 kDa up to 90 kDa when examined by SDS
PAGE. (Lambert, 1988; Wertz et al., 1989; Collins and
Mottet, 1992). Although the vast majority of the SH protein
is expressed in a non-glycosylated form, a small proportion
of the SH protein is also expressed as an immature N-linked
glycosylated form that exhibits endoglycosidase-H sensitivity.
A small proportion of the latter is further modified by the
addition of polylactosamine (Anderson et al., 1992a, 1992b).
The function of the different glycosylated forms of these
proteins is currently unclear. The proteomic analysis
described above suggests that the F protein is expressed in
at least two different glycosylated forms, providing evidence
that it also exhibits heterogeneity with respect to glycosyl-
ation. However, it is not clear if the polypeptide chains
within an individual F protein trimer are glycosylated
differentially or if glycosylation of the individual F protein
trimers is variable.
Maturation of F protein glycans is not required for efficient
RSV assembly
The above data provided evidence that during RSV infection,
the F protein exhibits heterogeneity with respect to the structure
of its attached N-linked glycans. We therefore used the α-
mannosidase inhibitors, deoxymannojirimycin (DMJ) and
swainsonine (SW), which inhibit N-linked glycan maturation
(reviewed in Elbein, 1991), to investigate the effect of such
maturation on the functionality of the F protein. The attached N-
linked glycans are synthesised initially as structures consisting
of mannose chains, which are then partially removed by the
cellular enzymes α-mannosidase 1 and α-mannosidase 2. This
leaves a mannose core (Fig. 3A) to which other glycan moieties,
such as N-acetyl-glucosamine and fucose, are added by specific
glycotransferases. This process converts the attached glycans
from simple structures, that consist almost entirely of mannose,
into structures that exhibit a high degree of complexity. DMJ
and SW inhibit the activity of α-mannosidase 1 and α-
mannosidase 2, respectively, which prevents maturation of the
attached glycans, and to varying degrees, the incorporation of
terminal sugar moieties (e.g., N-acetyl-glucosamine) into the
glycan chains.
Fig. 2. 2D SDS PAGE analysis of the F protein. Membrane proteins were isolated from cells and analysed by 2D SDS PAGE as described in Materials and methods.
(A) Proteins from virus-infected cells were separated and visualised directly by silver-staining. (B and C) Proteins were either non-treated (b) or PNGase F-treated (c)
prior to their separation by 2D SDS PAGE, transferred by Western blotting on to PVDF membranes and probed either with MAb169 (B) or PAb922 (C). The different
major (↓) and minor (*) F protein species are indicated. Also shown are PVDF membranes in which proteins from mock-infected cells (a) were transferred by Western
blotting and probed either with MAb169 or PAb922.
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[35S]methionine or [3H]glucosamine for 3 h in the absence (NT)
or presence of either DMJ or SW (Figs. 3B–D) after which the
cells were incubated for an extra 1 h in DMEM (containing non-
radioactive methionine) in the absence or presence of the
inhibitors. The F protein was isolated by radioimmunoprecipi-
tation (RIP) using MAb19 and examined using SDS PAGE(Figs. 3B and C). Analysis of the [35S]methionine-labelled
proteins revealed the cleaved, mature F protein as the major
form detected (Fig. 3B). In the absence of inhibitor, the F1
subunit was detected as a single protein species with a mass of
approximately 55 kDa and the F2 subunit migrated with a mass
of approximately 20 kDa. A small degree of size variation in the
protein products from the two cell lines was observed, which
Fig. 3. The effect of deoxymannojirimycin (DMJ) and swainsonine (SW) on F protein processing. (A) Schematic diagram showing the processing pathway of N-linked
glycans. Also shown are the stages in the pathway at which DMJ and SW inhibit the glycan maturation process. (Symbols: open circles—mannose; closed squares—
N-acetyl glucosamine; closed circles—galactose; diamond—sialic acid; triangle—fucose). RSV-infected Hep2 and Vero cells were either non-treated (NT), DMJ- or
SW-treated and radiolabelled with [35S]methionine (plate B) or D-[6-3H]glucosamine hydrochloride (plates C and D). The F protein (plates B and C) and G protein
(plate D) were isolated by RIP and examined by SDS-PAGE. The respective F and G protein species are indicated.
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Fig. 4. F protein heterogeneity is lost following DMJ-treatment. (A) RSV-infected Hep2 cells were labelled with [35S]methionine in the absence (NT) or presence of
either DMJ or SWand the F protein was isolated by RIP usingMAb19. The F protein was then either non-treated (−) or endo-H-treated (+) and examined by 15% SDS-
PAGE. The positions of the glycosylated (◂) and deglycosylated (*) F protein species are indicated. (B) The proteins from (a) non-treated or (b) DMJ-treated cells were
separated by 2D SDS PAGE and transferred by Western blotting on to PVDF membranes which were probed with MAb169. The position of the F1 subunit is
highlighted (black arrow).
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processing. Similar cell-specific changes have been reported for
the G protein (Garcia-Beato et al., 1996). The presence of DMJ
or SW did not affect the conversion of F0 into the mature F
protein by cellular protease activity and the levels of [35S]
methionine-labelled F protein were similar in both non-treated
and inhibitor-treated cells. However, a slight reduction in the
apparent molecular mass of the F2 subunit was observed in both
cell lines in the presence of the glycosylation inhibitors, which
is presumably due to changes in the structure of the attached
glycans. In particular, the relatively high levels of mannose,
which would be expected to be present in the F protein
following treatment with these α-mannosidase inhibitors, may
affect their apparent size when examined by SDS PAGE.
In a parallel analysis, the F protein was isolated from mock-
treated and DMJ- or SW-treated infected Hep2 and Vero cells
that were [3H]glucosamine-labelled and examined by SDS
PAGE (Fig. 3C). In both the absence and presence of SW,
protein species of similar intensities, which corresponded in size
to the F1 and F2 subunits, were visible (Fig. 3C). However, in
the presence of DMJ, a large reduction occurred in the levels of
[3H]glucosamine incorporated into the F1 and F2 subunits. This
is in contrast to the presence, in all samples, of similar levels of
[35S]methionine-labelled F protein being detected by SDS
PAGE (Fig. 3B). Thus, while there appears to be an
incorporation of glucosamine into the F protein subunits in
the presence of SW, only a minimal addition of terminal
glycans, such as glucosamine, is apparent in the presence of
DMJ.
In addition to isolation of the F protein, the G protein was
isolated from the [3H]glucosamine-labelled mock-treated and
DMJ-treated infected Hep2 and Vero cells by RIP using
MAb30, whose specificity has been described previously(Jeffree et al., 2003). Examination of the G protein by SDS
PAGE (Fig. 3D) showed protein products of the expected sizes
which were similar both in the presence or absence of DMJ. As
observed previously, the G protein expressed in Hep2 cells
differed in band pattern from that in Vero cells (Garcia-Beato et
al., 1996). However, compared to mock-treated cells, only a
small reduction in [3H]glucosamine labelling of Hep2 cells was
observed in the presence of DMJ and no obvious reduction
occurred in similarly treated Vero cells. Similarly, the size of the
G protein species was similar in both mock- and DMJ-treated
cells. This is consistent with the G protein being extensively
modified by O-linked glycosylation, a process that is not
affected by DMJ. This finding is consistent with previous
findings that tunicamycin, an inhibitor of N-linked glycosyla-
tion, did not interfere with the modification of the G protein by
O-linked glycosylation (Wertz et al., 1989). The results obtained
for F and G protein labelling in the presence and absence of
DMJ were similar in both cell lines, suggesting that the effect of
this inhibitor on processing of the RSV glycoproteins is not cell-
specific. Although the G protein in the RSV A2 sequence
contains four potential N-linked glycosylation sites, it is not
clear either how many of these are utilised or what role N-linked
glycosylation plays in the functionality of the G protein.
In a further analysis, the endoglycosidase-H (endo-H)-
sensitivity of the F protein in non-treated and inhibitor-treated
cells was examined. Endo-H is able to remove simple glycans
from proteins while mature glycan chains containing complex
sugars remain unaffected. RSV-infected Hep2 cells were pulse-
labelled with [35S]methionine for 3 h in the absence or presence
of the glycosylation inhibitors. The F protein was isolated by
RIP, incubated at 37 °C for 14 h in the presence or absence of
endo-H as described in Materials and methods and examined by
SDS PAGE (Fig. 4A). The F protein is expressed initially as the
Fig. 5. Distribution of the F protein in virus-infected cells following treatment with DMJ or SW. RSV-infected cells were either non-treated (NT) or treated with DMJ or
SW, labelled with MAb19 and visualised by fluorescence microscopy as described in Materials and methods. The presence of small virus filaments (VF) is highlighted.
295T.P. McDonald et al. / Virology 350 (2006) 289–301endo-H sensitive precursor, F0 (75 kDa), which is subsequently
modified by the addition of complex carbohydrates in the Golgi
apparatus to produce the endo-H-resistant form of the protein
(Collins and Mottet, 1991; Anderson et al., 1992a, 1992b).Fig. 6. Distribution of the F and G proteins within the envelope of RSV filaments. RSV
for FE SEM as described in Materials and methods. The cells were labelled either wit
presence of bound antibody detected using secondary antibody conjugated to 10 nm c
images. The individual images obtained using the secondary electron (SE) and backs
colloidal gold particles (white arrows) are highlighted.Maturation of the N-linked glycans coincides with the post-
translational cleavage of F0 into the F1 (55 kDa) and F2
(20 kDa) subunits. In both non-treated and inhibitor-treated
cells, the F0 is converted into a de-glycosylated, 60 kDa protein-infected cells were either non-treated (NT), SW- or DMJ-treated and processed
h MAb19 (F protein, plates A–D) or MAb30 (G protein, plates E and F) and the
olloidal gold particles. The bound gold was visualised as white spots in the BSE
catter electron (BSE) detectors are shown. The virus filaments (VF) and 10 nm
Fig. 7. Analysis of F protein levels in cell-released virus. Cell-released virus was
prepared from non-treated (NT), SW- or DMJ-treated [35S]methionine-labelled
cells as described in Materials and methods. The virus particles were detergent-
solubilised with lysis buffer and the F, N and P proteins isolated by RIP using
anti-RSV and examined either by (A) 7.5% or (B) 15% SDS PAGE.
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control in this analysis. In non-treated cells, the apparent mass
of the F protein subunits is unaffected by endo-H treatment,
showing, as expected, that it is converted into the endo-H
resistant form of the protein. In contrast, in the presence of
either DMJ or SW, the F protein was expressed in an endo-H
sensitive form, since treatment with the enzyme produces a shift
from 55 kDa to 50 kDa and a shift from 20 kDa to 10 kDa, the
expected sizes of the non-glycosylated F1 and F2 protein
subunits, respectively. This suggests that although different
levels of terminal glycans are incorporated into the F protein
following DMJ- and SW-treatment, in each case they have not
been fully processed into mature glycans.
The above data suggested that DMJ treatment prevented
heterogeneity of the F protein glycans. Evidence of the loss of
this heterogeneity following DMJ treatment was supported by
2D SDS PAGE (Fig. 4B). The migration pattern of the F1
subunit isolated from non-treated or DMJ-treated cells was
compared. In non-treated cells, several F1 subunit species were
detected which differed in their isoelectric points (Fig. 4B (a))
and were similar to those described above (Fig. 2A (b)). In
contrast, protein isolated from DMJ-treated cells migrated as a
single species (Fig. 4B (b)), which had undergone a shift to a
more basic isoelectric point, presumably as a result of the
absence of complex glycans following DMJ treatment.
Previous studies have shown that certain post-translational
modifications, such as cleavage of the F protein by proprotein
convertases, are required for RSV assembly (Bolt et al., 2000;
Sugrue et al., 2001). Thus the effect of these glycosylation
inhibitors on both virus assembly and on the incorporation of
the virus glycoproteins into virus filaments (VF) was examined.
Non-treated and inhibitor-treated virus-infected cells were
labelled with MAb19 and the distribution of the F protein was
examined by fluorescence microscopy. In all cases, the presence
of small VF was observed and the cells showed similar levels of
labelling, suggesting that neither DMJ nor SW appeared to
inhibit virus assembly or prevent targeting of the F protein into
progeny virus (Fig. 5). This is consistent with previous findings
by FACS analysis which had suggested that neither DMJ nor
SW reduced surface expression of the F protein in virus-infected
cells (MacLellan and Sugrue, data not shown).
The fluorescence microscopy results were confirmed by field
emission scanning electron microscopy (FE SEM) whose use in
the analysis of RSV-infected cells has been described previously
(Jeffree et al., 2003). This allows both visualisation of the
maturing RSV filaments in greater detail and the semi-
quantitative determination of glycoprotein levels (e.g., the F
protein) within the VF. FE SEM has an advantage over FACS
analysis since it makes possible the detection of signal present
on the VF, whereas FACS detects all surface signal (i.e.,
fluorescence) and does not distinguish between VF-associated
and non-VF-associated signal. Non-treated and inhibitor-treated
infected cells were labelled with MAb19 and the presence of
bound antibody was detected using secondary antibody
conjugated to 10 nm colloidal gold. The VF were visible
using the secondary electron (SE) detector (Fig. 6, plate A),
while the back scatter electron (BSE) detector allowed thevisualisation of bound MAb19 indicating the presence of the F
protein (Fig. 6, plates B–D). In the BSE images, the outline of
the VF can be seen due to the use of osmium tetroxide in the
specimen preparation which stains the VF and causes some
residual back scatter signal. However, in BSE mode, the
presence of colloidal gold is visible as small white spots on the
VF. These data show that similar levels of bound antibody were
present within the VF of both non-treated and treated cells,
suggesting that glycan maturation did not influence the
targeting of the F protein to the sites of virus assembly.
Furthermore, we noted the presence of similar levels of virus
filaments in the presence and absence of the α-mannosidase
inhibitors, suggesting that these inhibitors did not impair
budding efficiency.
The labelling pattern of the G protein in the absence or
presence of DMJ was also examined by FE SEM. In this
analysis, the G protein was detected with MAb30. In the
absence of inhibitor, a pattern of labelling was observed which
was similar to that observed previously (Jeffree et al., 2003). In
addition, similar levels of G protein labelling were observed
both in the absence or presence of DMJ, suggesting that
targeting of this protein into VF was unaffected by DMJ
treatment (Fig. 6, plates E and F). Although the pattern of
antibody labelling for the F and G proteins was similar in both
mock-treated and DMJ-treated cells, labelling of VF with
MAb30 was approximately three times more than that observed
with MAb19. The reason for this apparent difference in gold-
labelling is at present unclear but may be due to some masking
of the F protein epitope during fixation with glutaraldehyde.
Labelling of the VF with MAb19 was more sensitive to the
concentration of glutaraldehyde present in the initial fixation
solution than was found when labelling with MAb30. However,
these data show similar levels of the F and G proteins within the
virus envelope of mock-treated and DMJ-treated cells.
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content of cell-released virus to determine if the glycosylation
inhibitors caused a reduction in the levels of F protein
incorporated into cell-free virus. Hep2 cells were infected
with RSV in the absence or presence of the glycosylation
inhibitors and labelled with [35S]methionine. The total amount
of cell-free virus from these cells was harvested at 60 h PI as
described in Materials and methods. The virus particles were
solubilised with detergent to extract the virus-associated
proteins which were isolated by RIP using anti-RSV, a
composite antibody preparation which recognises the N, P
and F proteins (Wright et al., 1997). This analysis showed
similar amounts of the major structural proteins, including the
F1 and F2 subunits, in virus harvested from both non-treated
and inhibitor-treated cells (Figs. 7A and B), indicating that these
inhibitors did not impair either the levels of released virus or the
incorporation of these structural proteins into the released virus.
Thus, the FE SEM and RIP data provide evidence that efficient
incorporation of the F protein into virus particles is not
dependent upon glycan maturation. This suggests that these
inhibitors cause neither gross mis-folding of the F protein norFig. 8. The effect of α-mannosidase inhibitors on RSV infectivity. (A) Hep2 cells wer
cultures were left either untreated (NT) or treated with SW or DMJ. At 48 h PI, the
inverted microscope (Zeiss Axiovert 25). Virus-induced syncytia are highlighted (b
DMJ-treated cells harvested at 60 h PI, was measured using a microplaque assay asinhibition of its oligomerisation, otherwise interference both
with the transport of the F protein through the secretory pathway
and its subsequent incorporation into newly formed virus
particles would be expected.
Glycan maturation is required for virus-infectivity
Maturation of the F protein-associated N-linked glycans did
not appear to prevent virus assembly and therefore the effect of
glycan maturation on virus infectivity was examined. Hep2
cells were infected with RSV in the presence or absence either
of SW or DMJ and the virus produced both in the absence and
presence of these inhibitors was analysed further to determine if
they had any deleterious effect on virus infectivity. In the
absence of inhibitor, as expected, the appearance of extensive
syncytia was observed by 48 h PI (Fig. 8A, highlighted by black
arrow). A similar effect was observed with infected cells
incubated in the presence of SW. In contrast, cells treated with
DMJ exhibited a low level of syncytia formation and the cell
monolayer remained largely intact throughout the infection.
This suggested that in the presence of DMJ, the ability of the Fe either mock-infected or infected with RSVat a moi of 0.1. At 6 h PI, duplicate
cells were photographed using a Pentax K1000 camera attached to a low-power
lack arrows). (B). The infectivity of virus, recovered from non-treated, SW- or
described in Materials and methods.
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maturation of F protein-associated glycans is important for this
biological activity.
The virus was harvested from the inhibitor-treated and non-
treated cells at 60 h PI and the infectivity of the recovered virus
was measured (in the absence of added inhibitor) using a
microplaque assay as described previously (Cannon, 1987;
Sugrue et al., 2001). The infectivity of virus harvested from
SW-treated cells showed an approximate two-fold reduction
compared to that from non-treated cells whereas the effect of
DMJ treatment was much more dramatic with infectivity levels
reduced one hundred-fold (Fig. 8B).
The difference between the two α-mannosidase inhibitors
with regard to F protein processing and their respective
antiviral activities is unclear. DMJ inhibits α-mannosidase 1
while SW inhibits α-mannosidase 2. Thus, it appears that SW
inhibits glycan maturation at a later stage in the maturation
process. This suggests that in the presence of SW, a degree of
glycan maturation occurs, leading to the formation of hybrid
glycans and this has been observed previously (Elbein, 1984;
Moremen, 2002). In contrast, no maturation of the attached
glycans occurs in the presence of DMJ. It is possible, therefore,
that the virus glycoproteins may be able to accommodate some
loss of glycan maturation without a serious loss of biological
activity.
The data presented here provide evidence that maturation of
the glycans present on the virus glycoproteins is required for
virus infectivity. Furthermore, DMJ-treatment appears to have
a much more dramatic effect on the glycosylation status of the
F protein than on that of the G protein. Under conditions
where the maturation of N-linked glycans is prevented (i.e.,
DMJ-treatment), a 100-fold decrease in virus infectivity was
observed. Furthermore, DMJ treatment correlated with a vast
reduction in syncytia formation in virus-infected cells. These
two observations suggested that DMJ caused an impairment of
the F protein function. A reduction in syncytia formation via
some unidentified host cell factor that is involved in mediating
virus fusion cannot be unequivocally ruled out. However,
recent studies on another paramyxovirus, measles virus (MV),
showed that DMJ treatment neither prevented syncytia
formation in MV-infected Hep2 cells nor did it result in a
significant reduction is virus infectivity (Bolt et al., 1999).
Therefore, in contrast to the situation in RSV, the addition of
complex glycans to the MV glycoproteins appears not to be
required for mediating membrane fusion. Additionally, this
suggests that DMJ does not modify general host-cell factors
that may be required for virus-mediated cell fusion. In
contrast, we noted that SW-treatment produced no apparent
reduction in the syncytia levels, nor a significant effect on
virus infectivity. Since syncytia formation is an indicator of
fusion activity, it is possible that the ability of the virus to
mediate cell fusion is impaired which leads to a reduction in
virus infectivity.
RSV generated by reverse genetics, in which the G or SH
proteins are deleted, is able to replicate in tissue culture and
such studies have shown that only the F protein is required
for virus-mediated cell fusion (Karron et al., 1997; Whiteheadet al., 1999; Techaarpornkul et al., 2001). Although a reverse
genetics approach has suggested that the G protein may
facilitate virus binding, it has no significant involvement in
the virus-mediated cell fusion process (Techaarpornkul et al.,
2001). This suggests that the reduction in virus infectivity in
the presence of DMJ may be a consequence of aberrant
processing of the F protein. In several different paramyx-
oviruses, the ability of the respective fusion proteins to induce
fusion has been shown to be dependent upon the presence of
specific N-linked glycans (Malvoisin and Wild, 1994; Bolt et
al., 1999; McGinnes et al., 2001; von Messling and Cattaneo,
2003; Wang et al., 2004). In RSV, it has been suggested that
glycosylation of the F protein, and in particular the single
glycan moiety on the F1 subunit, is required for membrane
fusion (Zimmer et al., 2001b). These studies revealed that the
removal of glycan N500 from the F1 subunit resulted in a
dramatic reduction in F protein fusion activity, whereas
removal of the individual glycans from the F2 subunit
appeared to have no strong deleterious effect. These findings
have been confirmed in our laboratory by examining the
ability of the RSV F protein (A2 sequence) to mediate
membrane fusion following the selective removal of specific
glycosylation acceptor sites (Li, 2005). Thus, a role for glycan
N500 in the F protein-mediated cell fusion mechanism is
suggested and it is interesting to note that this glycan
attachment site is located within the heptad repeat region of
the F1 subunit (Chambers et al., 1990). Within viral fusion
proteins, heptad repeat sequences form structures that play an
important role during virus-induced cell fusion (reviewed in
Lamb, 1993; Dutch et al., 2000; Colman and Lawrence, 2003;
Morrison, 2003; Yin et al., 2005) and it is possible that
N500 may interact with these RSV F protein structures. The
results presented here suggest that F protein-induced cell
fusion, and hence virus infectivity, may also be dependent
both upon the structure of the attached glycan. Thus, an
indirect effect of glycan maturation on the fusion process is
implicated, possibly by facilitating the adoption of the fusion-
active form of the RSV F protein.
An alternative to the above explanation for our observations
is the possibility that glycan maturation is required for cell
attachment. Glycan maturation may be required for receptor
binding to susceptible cells and it is possible that DMJ may
block the attachment of newly assembled virus particles to the
cells thus preventing indirectly the formation of syncytia. It is
unlikely that DMJ would influence virus attachment by
affecting the RSV cell receptor heparin sulphate (HS), since
glycoaminoglycans (GAGs), such as HS, are synthesised by
cellular pathways that do not involve α-mannosidase 1, and
furthermore, GAGs are attached to serine residues within
proteins via O-linked glycosylation (reviewed in Hacker et al.,
2005). However, the role played by the F protein in virus
binding to cell surface GAGs has been demonstrated previously
(Karger et al., 2001) and more recent evidence suggests an
involvement of the F2 subunit during the initial stages of cell
attachment (Schlender et al., 2003). It is possible that the
structure of the glycans present within the F2 subunit may be
important for this interaction.
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in certain high-risk groups within the adult population such as
the elderly and immunocompromised and there is currently no
effective vaccine to protect such individuals from infection.
The only currently effective preventative measure is the use of
humanised monoclonal antibodies, which are both expensive
and require specialists for their administration. The reduction
in virus infectivity induced by DMJ may have implications for
the development of strategies to prevent RSV infection in
these high-risk groups. Toxicity data for DMJ in animals are
not available and it is not proposed that this specific
compound would be used to control RSV infection. However,
this class of compound may provide a means of controlling
RSV infection by inhibiting the maturation of associated
glycans and hence targeting the biological activity of the F
protein. It is envisaged that DMJ may serve as a starting point,
which, in conjunction with combinatorial chemistry, can be




The RSV A2 strain was used throughout this study. The
Hep2 cell line was maintained in Dulbecco's Modified Eagle's
Medium (DMEM) containing 10% foetal calf serum (FCS) and
antibiotics.
Antibodies and inhibitors
The F2 protein subunit polyclonal antibody (PAb922) was
prepared as follows. A branched peptide corresponding to the
sequence TELQLLMOSTQAT, which is present in the F2
domain of the RSV A2 strain, was synthesised on tetravalent
(Lys)2-Lys-β-Ala-Wang resin (Novochem) using standard 9-
fluorenylmethoxycarbonyl-solid phase chemistry and an
Advanced ChemTech 348 Ω automated peptide synthesiser.
The resulting peptide was used to immunise rabbits. The F
protein monoclonal antibody (MAb169) was prepared from
recombinant F protein expressed in E. coli (Rixon et al.,
2004). MAb19 and MAb30 were gifts from Geraldine Taylor
(IAH, Compton, UK) and the anti-RSV monoclonal antibody
(NCL-RSV3) was purchased from Novocastra Laboratories.
The glycosylation inhibitors, deoxymannojirimycin and swain-
sonine, were purchased from Calbiochem and stock solutions
were prepared in PBSA and used at 2 mM and 0.4 μM,
respectively.
Radiolabelling
Cell monolayers were washed with PBSA and incubated in
DMEMminus either methionine or glucose containing 100 μCi/
ml [35S]methionine or D-[6-3H]glucosamine hydrochloride,
respectively. When labelling was performed in the presence of
inhibitors, the cells were treated with the inhibitors both for 1 h
prior to radiolabelling and throughout the period of labelling. Inpulse-chase experiments the chase was performed in normal
DMEM containing methionine.
Radioimmunoprecipitation (RIP)
This was performed as described previously (Sugrue et al.,
2001). Briefly, cell monolayers were extracted at 4 °C in lysis
buffer (1% NP-40, 0·1% SDS, 150 mM NaCl, 1 mM EDTA,
2 mM PMSF, 20 mM Tris–HCl, pH 7.5) and the clarified lysate
incubated with the primary antibody. The immune complexes
were isolated with protein A-Sepharose and the F protein
examined by SDS-PAGE. [35S]methionine-labelled protein
bands were detected using a Bio-Rad personal Fx phosphor-
imager and analysed with Quantity one software (Bio-Rad, ver.
4) whereas D-[6-3H]glucosamine-labelled proteins were
detected by fluorography. Apparent molecular masses were
estimated using 14C-methylated proteins (Amersham) in the
molecular mass range 14·3–220 kDa.
Endoglycosidase digestion
Protein samples were incubated at 100 °C for 10 min in
denaturation buffer (0·5% SDS, 1% mercaptoethanol). The
samples were then made up to a final concentration of
either 50 mM sodium phosphate, 1% NP-40, pH 7·5 or
50 mM sodium citrate, pH 5·5 and incubated at 37 °C for
14 h with 1000 u PNGase F (NEB) or 1000 u endo-H
(NEB), respectively.
2D SDS PAGE
Membranes were isolated from mock- and virus-infected
cells as described previously (McDonald et al., 2004).
Briefly, the isolated membranes were washed twice with
10 mM Tris pH 7.4/1 mM MgCl2, resuspended in
denaturation buffer and incubated at 100 °C for 10 min.
The denatured proteins were assayed for protein using the
Amersham PlusOne 2-D Quant kit and 50 μg of each sample
were incubated overnight at 37 °C in the absence or presence
of 1000u PNGase F. Proteins were then precipitated in 6%
TCA containing 60 mM sodium deoxycholate, resuspended
in urea/CHAPS buffer (8 M urea, 2.6 M thiourea, 4%
CHAPS, 20 mM Tris pH 7.4, 30 mM DTT, 2% IPG buffer
pH 3–10, 2 mM PMSF, EDTA-free complete protease
inhibitors) and incubated at room temperature overnight.
40 μg protein in 125 μl were then added to each 7 cm pH
3–10 IPG dry strip and the strips were hydrated overnight at
20 °C. The proteins were separated by isoelectric focusing
using the IPGPHOR isoelectric focusing system with the
following programme. Step 1: 500 V for 30 min (250 Vh);
Step 2: 1000 V for 30 min (500 Vh); Step 3: 8000 V for 1 h
(8000 Vh). After completion of the first dimension, the IPG
strips were incubated in SDS equilibration buffer (25 mM
Tris base, 192 mM glycine, 0.1% SDS, 0.01% DTT) for
15 min at room temperature. The proteins were then
separated in the second dimension by SDS PAGE prior to
Western blot analysis.
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Western blotting was performed as described previously
(Brown et al., 2002). Briefly, proteins were separated by SDS
PAGE after which they were transferred by Western blotting
on to PVDF membranes. The membranes were washed,
blocked with 1% Marvel, 0.05% Tween in PBSA and probed
with specific primary antibodies for 1 h. The membranes
were then washed, probed either with goat anti-mouse or
anti-rabbit IgG (whole molecule) peroxidase conjugate
(Sigma) as appropriate and the protein bands visualised
using the ECL protein detection system (Amersham).
Apparent molecular masses were estimated using Rainbow
protein markers (Amersham) in the molecular weight range
14.3–220 kDa.
Field emission scanning electron microscopy (FE SEM)
This was performed as described previously (Jeffree et al.,
2003). Cells on glass coverslips were infected with RSV and
incubated overnight at 33 °C in the absence or presence of the
glycosylation inhibitors. Cells were fixed with 0.1% glutaral-
dehyde in PBS at 4 °C for 30 min. The fixed monolayers were
incubated in PBS supplemented with 2 mM lysine for 20 min
and then washed extensively with PBS. The cells were
incubated at 25 °C for 4 h with MAb19 or MAb30, washed,
and then incubated for a further 4 h with goat anti-mouse IgG
(whole molecule) conjugated to 10 nm colloidal gold. The
monolayers were washed with PBS, fixed with 2.5%
glutaraldehyde in PBS and processed for SEM. The samples
were visualised in a Hitachi 4700F field emission scanning
electron microscope using appropriate settings and digital
images were recorded using Hitachi FE PCSEM (ver 3.2)
software.
Isolation of [35S]methionine-labelled virus by sucrose gradient
centrifugation
Three sub-confluent T75 flasks containing Hep2 cells were
infected with RSVat a moi of 1.0 and incubated at 33 °C. At 6 h
PI, the cells were washed with PBS and 20 ml DMEM minus
methionine containing 100 μCi/ml [35S]methionine was added.
The flasks were either left untreated (NT) or incubated in the
presence of 0.4 μM swainsonine (SW) or 2 mM deoxymanno-
jirimycin (DMJ). The All subsequent steps were performed at
4 °C. The tissue culture medium was harvested at 60 h PI and
clarified by low speed centrifugation (2000 g, 10 min). Equal
volumes (18 ml) of the clarified medium was then centrifuged
at 26,000 × g for 90 min and the pelleted material resuspended
in 1 ml Hanks buffered saline solution (HBSS) using a
sonicating water bath. The resuspended material was overlaid
on a 25–55% sucrose gradient (in HBSS) and centrifuged at
26,000 × g for 8 h at 4 °C. The virus band was harvested (2 ml)
from the gradient (typically at 40% sucrose), resuspended in
HBSS and the virus pelleted by centrifugation at 26,000 × g for
90 min. The virus was then resuspended in HBSS and used in
RIP assays.Microplaque titration of RSV preparations
Titrations were performed in 96-well tissue culture plates
which were seeded with Hep2 cells (Cannon, 1987). Tissue
culture medium from non-treated and treated mock- and RSV-
infected cells was subjected to low-speed centrifugation to
remove cell debris (2000 × g/10 min), serially diluted in
DMEM + 2% FCS and 50 μl per well of the mock-infected or
virus-infected cell supernatant adsorbed for 2 h at 33 °C. After
adsorption, the inoculum was replaced with DMEM + 2% FCS
and incubated at 33 °C for 48 h. All further manipulations were
performed at 25 °C. The monolayers were washed with PBS
and fixed with methanol for 20 min. The fixative was removed
and the plates were washed with PBS. The monolayers were
incubated with an anti-RSV MAb (Novacastra) (50 μl per well
diluted 1/100) for 60 min, washed with PBSA and then
incubated for a further 60 min with a rabbit anti-mouse IgG
MAb conjugated to HRP (50 μl per well diluted 1/100). The
plates were washed with PBS, stained with 200 μg/ml 3-amino-
9-ethylcarbazole, 0·05% hydrogen peroxide, 20 mM sodium
acetate pH 5·5 and the microplaques were counted using a low-
power inverted microscope.
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